- Todos Medical ( OTCQB:TOMDF ) said its laboratory Provista Diagnostics completed CLIA validation and commercially launched lesion and saliva-based monkeypox PCR testing in the U.S.
- Provista will collect saliva samples matched with lesion swabs from confirmed MonkeyPox cases before launching a standalone laboratory-developed test (LDT) targeted at identifying monkeypox in the pre-symptomatic stage, the company said in an Aug. 22 press release.
- Todos noted that Provista currently has PCR automation capacity to run 25K PCR tests per day with ongoing efforts to increase the capacity to 50K tests per day.
- The Israeli company added that it is also preparing validation plans for an IgM/IgG blood-based monkeypox LDT to confirm recent infection as part of a planned MonkeyPox Panel.
For further details see:
Todos launches monkeypox PCR test in US